1. An Explorative Study of CYP2D6's Polymorphism in a Sample of Chronic Pain Patients.
- Author
-
Fanelli, Andrea, Palazzo, Chiara, Balzani, Eleonora, Iuvaro, Alessandra, Pelotti, Susi, and Melotti, Rita Maria
- Subjects
- *
CHRONIC pain , *CLINICAL trials , *DNA , *GENETIC polymorphisms , *RESEARCH , *GENOTYPES , *CYTOCHROME P-450 - Abstract
Background A proper antalgic treatment is based on the use of titrated drugs to provide adequate relief and a good tolerability profile. Therapies have a variable effectiveness among subjects depending on medical and genetic conditions. CYP2D6 variations determine a different clinical response to most analgesic drugs commonly used in daily clinical practice by influencing the drugs' pharmacokinetics. This study was a monocentric clinical trial exploring the CYP2D6 variants in 100 patients with a diagnosis of chronic pain. Methods DNA was extracted to evaluate the genotype and to classify patients as normal-fast (gNMs-F), normal-slow (gNMs-S), ultrarapid (gUMs), intermediate (gIMs), and poor metabolizers (gPMs) using the Activity Score (AS). Information on therapies and general side effects experienced by patients was collected. Nongenetic co-factors were evaluated to examine the discrepancy between metabolic profile predicted from genotype (gPh) and metabolic profile (phenocopying). Results The distribution of our data underlined the prevalence of the gNMs-F (67%), whereas gNMs-S were 24%, gIMs 6%, gPMs 3%, and no gUMs were found, resulting in 33% of patients with reduced metabolic activity. In the analyzed population sample, 86% and 56% of patients, respectively, took at least one or two drugs inhibiting in vitro activity of the CYP2D6 enzyme. Conclusions Over one-third of the enrolled patients showed altered CYP2D6 enzymatic metabolic activity, with a risk of phenocopying potentially due to polypharmacology. Trial registration ClinicalTrials.gov ID: NCT03411759. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF